CN100556418C - 一种降脂保健品 - Google Patents
一种降脂保健品 Download PDFInfo
- Publication number
- CN100556418C CN100556418C CNB2006101316149A CN200610131614A CN100556418C CN 100556418 C CN100556418 C CN 100556418C CN B2006101316149 A CNB2006101316149 A CN B2006101316149A CN 200610131614 A CN200610131614 A CN 200610131614A CN 100556418 C CN100556418 C CN 100556418C
- Authority
- CN
- China
- Prior art keywords
- natto
- fat
- blood
- fat reducing
- lentinan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000001603 reducing effect Effects 0.000 title claims abstract description 25
- 230000036541 health Effects 0.000 title claims abstract description 13
- 235000013557 nattō Nutrition 0.000 claims abstract description 26
- 229920001491 Lentinan Polymers 0.000 claims abstract description 14
- 229940115286 lentinan Drugs 0.000 claims abstract description 14
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 12
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims abstract description 12
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 9
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 11
- 240000000599 Lentinula edodes Species 0.000 claims description 9
- 235000001715 Lentinula edodes Nutrition 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 244000269722 Thea sinensis Species 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 244000063299 Bacillus subtilis Species 0.000 claims description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 6
- 238000010025 steaming Methods 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 239000003518 caustics Substances 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 3
- 238000012869 ethanol precipitation Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 150000002333 glycines Chemical class 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 239000002893 slag Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 27
- 239000008280 blood Substances 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 18
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 5
- 208000007536 Thrombosis Diseases 0.000 abstract description 4
- 230000036772 blood pressure Effects 0.000 abstract description 4
- 208000029078 coronary artery disease Diseases 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 230000000840 anti-viral effect Effects 0.000 abstract description 3
- 230000037356 lipid metabolism Effects 0.000 abstract description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 2
- 230000001133 acceleration Effects 0.000 abstract description 2
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 2
- 230000001804 emulsifying effect Effects 0.000 abstract description 2
- 239000008103 glucose Substances 0.000 abstract description 2
- 230000008092 positive effect Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 241001122767 Theaceae Species 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 22
- 241000700159 Rattus Species 0.000 description 14
- 235000013305 food Nutrition 0.000 description 12
- 238000012360 testing method Methods 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 9
- 201000005577 familial hyperlipidemia Diseases 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 235000013616 tea Nutrition 0.000 description 7
- 239000000284 extract Substances 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229940086319 nattokinase Drugs 0.000 description 3
- 108010073682 nattokinase Proteins 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010058646 Arcus lipoides Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 240000007930 Oxalis acetosella Species 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 235000010240 Paullinia pinnata Nutrition 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- -1 flavanol compound Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种降脂保健品,是由纳豆粉65-83%、香菇多糖1.0-2.5%、葛根素2.8-7.8%、茶多酚8-25%按重量混合制成。这些成分相互配合,协同作用,乳化血脂、防止氧化、加速脂质代谢、最终排除脂肪收起的毒性,从而降低血脂、预防动脉硬化和冠心病的发生,提高机体免疫力、增强体质的作用。本发明的明显效果有:降低血脂、血糖、血压、去脂减肥、增强免疫、溶解血栓、抗病毒、抗肿瘤。
Description
技术领域:
本发明涉及一种降低血脂的保健食品。
背景技术:
高脂血症是指血清中胆固醇(TC)、甘油三酯(TG)和(或)低密度脂蛋白(LDL)过高和(或)血清高密度脂蛋白(HDL)过低的一种全身脂代谢异常。凡是血清胆固醇>5.72毫摩尔/升(220毫克/分升)或(和)甘油三酯>1.70毫摩尔/升(150毫克/分升)或(和)高密度脂蛋白64毫摩尔/升(140毫克/分升)者,可诊断为高脂血症。高脂血症初期多数没有临床症状,但是没有及时纠正,对身体的损害是隐匿、逐渐、进行性和全身性的。它的直接损害是加速全身动脉粥样硬化,因为全身的重要器官都要依靠动脉供血、供氧,一旦动脉被粥样斑块堵塞,就会导致严重后果。动脉硬化引起的肾功能衰竭等,都与高脂血症密切相关。大量研究资料表明,高脂血症是脑卒中、冠心病、心肌梗死、心脏猝死独立而重要的危险因素。此外,高脂血症也是促进高血压、糖耐量异常、糖尿病的一个重要危险因素。高脂血症还可导致脂肪肝、肝硬化、胆石症、胰腺炎、眼底出血、失明、周围血管疾病、跛行、高尿酸血症。有些原发性和家族性高脂血症患者还可出现腱状、结节状、掌平面及眼眶周围黄色瘤、青年角膜弓等。
目前治疗高脂血症的药物多数是化学合成的化学药品或由几种中药组成的中药复方,前者长期使用出现毒性,且效果不理想,后者作用机制不明确,很难掌握有效成分的标准化和定量化。因此目前从常用的食品、保健品以及天然物中筛选降血脂有效成分,然后组合这些有效成分开发毒性低、作用强的降血脂药物或保健品,是很有前景的开发途径。但市场上缺少十分有效的降血脂的保健品。
发明内容
本发明的目的是由常用的食品、天然物中筛选具有降血脂作用且无毒、无副作用的降血脂有效成分,再把这些有效成分科学加工,合理配比制备降血脂保健食品。
常用食品纳豆、香菇、绿茶及药食两用中药葛根具有降血脂作用,同时通过研究证明了其降血脂有效成分。本发明所说的配比是这样的,由香菇中提取的香菇多糖、纳豆精制粉末、药食两用中药葛根中提取的葛根素及绿茶中提取的茶多酚组成。这些成分相互配合,协同作用,乳化血脂、防止氧化、加速脂质代谢、最终排除脂肪收起的毒性。从而降低血脂、预防动脉硬化和冠心病的发生,提高机体免疫力、增强体质的作用。
本发明的技术方案由下列组份按重量百分含量混合组成:
纳豆粉65-84% 香菇多糖1.0-2.5%
葛根素2.8-7.8% 茶多酚8-25%。
为确证产品质量,所有工作均应在洁净的干燥环境内进行。
1)香菇多糖的提取,香菇多糖的提取应避免在强酸、碱溶液中进行,否则极易造成香菇多糖中糖苷键断裂及构象变化。先将香菇子实体粉碎,用90-100℃水搅拌浸提3-5h,2-3次,再用5moI/L氢氧化钠液抽提,初步将多糖分为水溶和碱溶2部分。然后除去香菇渣,上清液树脂法除去小分子杂质,经乙醇沉淀后可得粗品。
2)纳豆粉的制备,取精选后的黄豆用水浸泡10-24小时,使其充分泡开后在100℃以上(含100℃)温度下蒸煮20-60分钟,蒸煮后的熟豆冷却至20-40℃时,均匀喷入纳豆菌液,在温度35-45℃、相对湿度50-90%条件下发酵培养18-30小时。将发酵好(产生较多的透明粘丝)的纳豆置于0-10℃冷藏室内冷藏24小时以上,取出,进行冷冻干燥,粉碎,过40-80目筛,即得。
3)茶多酚由市场购入。
4)葛根素由市场购入。
本保健品按上述原料混合均匀后可以装入0号胶囊进行包装。
纳豆是大豆通过纳豆菌经过发酵而形成的一种民间食品。纳豆不仅含有丰富的蛋白质,还含有卵磷脂、皂苷、低聚糖、异黄酮、纳豆激酶、超氧化歧化酶、蛋白抑制酶、多种维生素、19种氨基酸、22种微量元素等多种对人体非常有益的成分。多吃纳豆对人体健康的益处很多,可防治心脏病、中风、癌症、骨质疏松.肥胖症以及病原菌引起的消化道疾病。而且,至令还未发现食用纳豆对人体有任何毒副作用。由于纳豆的医疗保健作用得到越来越多和越来越广泛的承认,目前,纳豆已成为盛行于日本、加拿大、美国和欧洲一些国家的一种保健食品,在我国纳豆做为一种普通食品和保健品正在普及。纳豆已成为举世公认的医疗保健食品,是因为不仅其原料大豆是一种营养保健型食品,而且,纳豆枯草芽孢杆菌(Bacillus natto)在发酵大豆的过程中又分泌和合成了很多种酶类,维生素、氨基酸及其它只有纳豆特有的营养素和生理活性物质,如纳豆激酶(Nattokinase,NK)、Pylazine、抗菌肽、VK2。其中,NK和Pylazine是两种在人体内直接和问接溶解血栓的活性物质,既可以阻止血栓的形成又可以溶解血栓,网此它们可以有效地预防和治疗心肌梗死、脑血管梗塞,中风等死亡率症。另外纳豆中含有必需脂肪酸、维生素E、低聚糖、膳食纤维、黄酮类、皂素等营养保健物质,这些营养物质具有降血脂、降血压,防止动脉硬化等保健功能可用于高血脂、高血压、糠尿病、心脏病等人群的食品和保健食品。纳豆除了比大豆更易于吸收外,其含有的亚油酸和卵磷脂有利于清洗血管中沉积的胆固醇,净化血液和促使细胞新陈代谢。纳豆蛋白质有利于提高血管弹性,防止高血压的作用。
香菇〔Lentinula edodes(Berk.)Pegler〕,又名香菌、花菇,是一种重要的食药用栽培真菌。香菇多糖是从香菇子实体中分离到的一种分子量在40-80万之间的p-1,3-葡聚糖,具有抗病毒、抗肿瘤、调节免疫功能,临床主要用于胃癌、肺癌、肠癌及癌性胸腹水等恶性肿瘤的治疗,另外对提高肝炎及艾滋病人的免疫功能等均有较好的作用。通过近几年的研究证明,香菇具有降血脂和软化血管作用,其中主要有效成分是香菇多糖,香菇多糖降血脂作用中降低血胆固醇作用最明显。
茶多酚是一种从茶叶中提取出来的纯天然抗氧化剂,含有儿茶素、花青素、黄烷醇类、花色柑、黄酮醇类和酚酸等6种成分,具有抗菌、抗癌、抗衰老、抗紫外线和消除自由基作用。近来的药理研究表明,茶多酚具有,去脂减肥、降低血糖和胆固醇、预防心血管疾病、抑制肿瘤细胞等药理功能。
葛根素是豆科植物葛的干燥根中提取并分离出来的异黄酮类化合物,化学各为4,7-二羟基-8-β-D葡萄糖异黄酮。常用于治疗高血压、冠心病、高粘血症、心绞痛、脑缺血。葛根素通过对血管平滑肌内皮素和血液中一氧化氮的平衡调节,达到保护心脑和防止动脉硬化作用的纯天然植物提取物,目前是全世界临床治疗心脑血管疾病的主要药物之一。近年来研究表明,葛根素具有降脂,降压双重调节作用而受到注目。葛根素的降血脂作用中降低胆固醇作用特别明显。
本发明组分的明显效果如下:降低血脂、血糖、血压、去脂减肥、增强免疫、溶解血栓、抗病毒、抗肿瘤。
利用本发明进行降血脂药理实验的结果如下:
1材料与方法
1.1实验药品由延边大学草仙药业提供
1.2实验动物和分组
实验动物采用SD大鼠140-160g雌雄各半,由延边大学医学院动物室提供。试验分正常对照组(I组,喂普通饲料),高脂对照组(II组,喂高脂饲料),试验组分大、中、小三个剂量组(III、IV、V组,喂高脂饲料,并每日灌胃3个不同剂量的本发明胶囊)。每组12只大鼠。
1.3高脂饲料 取91.5%普通基础饲料粉、1.3%纯胆固醇、7%熟猪油及牛胆酸钠0.2%混合均匀,做成颗粒将做高脂饲料。
1.4降脂试验 试验大鼠随机分组后,称重,分别取尾血测定血清中血脂浓度。按常规自由摄食不同的饲料。自由饮水,每10天称重1次。一个月后,麻醉取肝门静脉血测定血脂及血液流变学指标。
1.5血脂测定 血清总胆固醇(TC),用高铁-醋酸-硫酸显色法;血清甘油三酯(TG)用异丙醇抽提,乙酰丙酮显色法;血清高密度脂蛋白胆固醇(HDL-C),用磷钨酸钠-镁沉淀后,按文献法进行测定;低密度脂蛋白胆固醇(LDL-C),根据公式进行推算,即LDL-C=TC-(HDL-D+1/5TG)。
2结果
2.1本发明胶囊对大鼠血清总胆固醇的影响。见表1。喂普通饲料的正常对照组(I组),试验前后血清胆固醇含量没有显著性差异;高胆固醇组(II组)试验前后血清胆固醇含量有显著性差异,给药组(III、IV、V组)与高胆固醇组相比有显著性差异,而且随着剂量的增加胆固醇的含量下降。可见本发明胶囊有阻止大鼠血清胆固醇升高的作用。
表1本发明胶囊对大鼠血清胆固醇的影响
注:与II组比较,*示p<0.05,**示p<0.01,下表同。
2.2本发明胶囊对大鼠血清甘油三酯的影响。见表2。喂普通饲料的正常对照组(I组),试验前后血清甘油三酯含量没有显著性差异;高脂组(II组)试验前后血清甘油三酯含量有显著性差异,给药组(III、IV、V组)与高脂组(II组)相比有显著性差异,而且随剂量的增加甘油三脂含量下降。可见本发明胶囊有阻止大鼠血清甘油三酯升高的作用。
表2本发明胶囊对大鼠血清甘油三酯的影响
2.3本发明胶囊对大鼠血清高密度脂蛋白胆固醇影响。其结果见表3。喂普通饲料的正常对照组(I组),试验前后血清高密度脂蛋白胆固醇没有显著性差异;
表3本发明胶囊对大鼠血清高密度脂蛋白胆固醇的影响
高脂组(II组)试验前后血清高密度脂蛋白胆固醇有显著性差异,大剂量给药组(V)和中剂量给药组(III)与高脂组(II)比较有显著性差异,但是低剂量给药组(IV)与高脂组(II)相比无显著性差异。可见本发明胶囊在大剂量的时候有增高大鼠血清高密度脂蛋白胆固醇的作用。
2.4本发明胶囊对大鼠血清低密度脂蛋白胆固醇影响。见表4。结果同2.3。
表4本发明胶囊对大鼠血清低密度脂蛋白胆固醇的影响
4结论:高脂模型组与正常对照组相比TC、TG、高密度脂蛋白胆固醇有显著性差异。说明本胶囊阻碍由高脂饲料引起的大鼠血脂的升高。
具体实施方式:
香菇多糖的提取,将香菇子实体粉碎,用90-100℃水搅拌浸提3-5h,2-3次,再用5moI/L氢氧化钠液抽提,初步将多糖分为水溶和碱溶2部分。然后除去香菇渣,上清液树脂法除去小分子杂质,经乙醇沉淀后可得粗品。
纳豆粉的制备,取精选后的黄豆用水浸泡10-24小时,使其充分泡开后在100℃以上(含100℃)温度下蒸煮20-60分钟,蒸煮后的熟豆冷却至20-40℃时,均匀喷入纳豆菌液,在温度35-45℃、相对湿度50-90%条件下发酵培养18-30小时。将发酵好(产生较多的透明粘丝)的纳豆置于0-10℃冷藏室内冷藏24小时以上,取出,进行冷冻干燥,粉碎,过40-80目筛,即得。
茶多酚和葛根素由市场购入。
由上法制备的纳豆粉327.6g,粗香菇多糖(香菇多糖含量20%)31.37g,葛根素提取物(葛根素含量40%)50.43g,茶多酚40.6g,混合均匀后装入0号胶囊,制备1000粒,每粒重0.45g。
Claims (2)
1、一种降脂保健品,由下列组份按重量百分含量混合组成:
纳豆粉65-84% 香菇多糖1.0-2.5%
葛根素2.8-7.8% 茶多酚8-25%,
其中,所述的纳豆粉是按下列方法制成:取精选后的黄豆用水浸泡10-24小时,使其充分泡开后在100℃以上的温度下蒸煮20-60分钟,蒸煮后的熟豆冷却至20-40℃时,均匀喷入纳豆菌液,在温度35-45℃、相对湿度50-90%条件下发酵培养18-30小时,将发酵好的纳豆,即产生较多的透明粘丝的纳豆置于0-10℃冷藏室内冷藏24小时以上,取出,进行冷冻干燥,粉碎,过40-80目筛,即得;
所述的香菇多糖是按下列方法制成:先将香菇子实体粉碎,用90-100℃水搅拌浸提3-5小时,2-3次,再用5mol/L氢氧化钠液抽提,初步将多糖分为水溶和碱溶两部分,然后除去香菇渣,上清液树脂法除去小分子杂质,经乙醇沉淀后得粗品。
2、根据权利要求1所述的一种降脂保健品,其特征在于用0号胶囊填充组成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006101316149A CN100556418C (zh) | 2006-11-02 | 2006-11-02 | 一种降脂保健品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006101316149A CN100556418C (zh) | 2006-11-02 | 2006-11-02 | 一种降脂保健品 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1957971A CN1957971A (zh) | 2007-05-09 |
CN100556418C true CN100556418C (zh) | 2009-11-04 |
Family
ID=38069923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006101316149A Expired - Fee Related CN100556418C (zh) | 2006-11-02 | 2006-11-02 | 一种降脂保健品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100556418C (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101874629A (zh) * | 2010-05-24 | 2010-11-03 | 崔晓廷 | 一种全营养多功能的复方沙棘纳豆保健品 |
CN101874628A (zh) * | 2010-05-24 | 2010-11-03 | 崔晓廷 | 一种全营养多功能的复方纳豆松花粉保健品 |
CN102342496B (zh) * | 2010-07-27 | 2013-04-17 | 李光敏 | 一种北虫草纳豆制品的制备方法 |
CN103330036A (zh) * | 2013-07-22 | 2013-10-02 | 北京绿源求证科技发展有限责任公司 | 一种预防高血压的食品养生茶冲剂 |
CN103719864A (zh) * | 2014-01-10 | 2014-04-16 | 东北师范大学 | 一种降血糖纳豆组合胶囊及其制备方法 |
CN104397701A (zh) * | 2014-12-10 | 2015-03-11 | 韦星平 | 降血脂天然食品添加剂 |
CN104585766A (zh) * | 2015-02-05 | 2015-05-06 | 广州赛莱拉干细胞科技股份有限公司 | 一种组合物及其制备方法与应用 |
CN104814429A (zh) * | 2015-04-10 | 2015-08-05 | 山东安然纳米实业发展有限公司 | 一种具有保肝、护肝、调节血脂功能的保健食品 |
CN107412753A (zh) * | 2017-08-08 | 2017-12-01 | 江苏天美健大自然生物工程有限公司 | 一种含纳豆激酶的控释片保健品及其制备方法 |
CN111480758A (zh) * | 2019-01-29 | 2020-08-04 | 金振库 | 一种纳豆蒲黄固体饮料及其制备方法 |
CN110089759A (zh) * | 2019-05-07 | 2019-08-06 | 朱国强 | 一种适用于心脑血管疾病患者食用的复合多酶食品 |
CN110089758A (zh) * | 2019-05-07 | 2019-08-06 | 朱国强 | 一种含活性地龙蛋白纳豆激酶复合多酶食品及其制备方法 |
CN110089760A (zh) * | 2019-05-07 | 2019-08-06 | 朱国强 | 一种含活性地龙蛋白纳豆激酶复合多酶食品的加工工艺 |
-
2006
- 2006-11-02 CN CNB2006101316149A patent/CN100556418C/zh not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
葛根素的药理作用及临床应用新进展. 戴琳等.海峡药学,第16卷第6期. 2004 * |
Also Published As
Publication number | Publication date |
---|---|
CN1957971A (zh) | 2007-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100556418C (zh) | 一种降脂保健品 | |
CN101347241B (zh) | 纳米功能健康食品及其加工方法 | |
CN102423375A (zh) | 一种降血脂保健品 | |
CN103099089A (zh) | 一种降糖、降压、通便减肥、抗疲劳、改善性功能保健品及其生产工艺 | |
CN101664184A (zh) | 一种降血脂的保健品及其制作方法 | |
CN106901118B (zh) | 具有辅助降血糖作用的固体饮料及其制备方法 | |
CN1911102B (zh) | 解酒保健组合物及其生产方法 | |
CN102132874A (zh) | 五谷营养产品 | |
Basharat et al. | Nutritional and functional profile of carob bean (Ceratonia siliqua): A comprehensive review | |
WO2008067315A1 (en) | Therapeutic composition from goji (lycium barbarum l.), methods of making and using | |
CN101884359A (zh) | 五谷咖啡 | |
CN100444746C (zh) | 一种高寒山区作物精制健康食品及其加工工艺 | |
CN101664180B (zh) | 一种具有保健功效的营养复合剂及其制备方法 | |
CN105533446A (zh) | 一种具有保健作用的营养麦片及其制备方法 | |
CN105795292A (zh) | 一种玉参饮品及其制备方法 | |
KR102137136B1 (ko) | 호박 가수분해 추출물, 구약감자 가수분해 추출물, 강황 추출물 및 카카오닙스 추출물을 포함하는 조성물 | |
CN107692195A (zh) | 一套适用于脑中风病人鼻饲的间餐营养餐包及其制备方法 | |
KR101534142B1 (ko) | 혼합 생약 추출물을 이용한 대사성질환 예방 및 치료용 조성물 | |
KR20170095646A (ko) | 발효발아현미와 와송 추출물을 함유하는 항당뇨 활성 효과를 갖는 조성물의 제조방법 | |
CN109258957A (zh) | 一种预防呼吸道疾病的猪饲料的配方及其制备方法 | |
CN108450941A (zh) | 一种调节脂代谢的膳食组合物 | |
CN104585574A (zh) | 蜂胶软胶囊产品及其制备 | |
CN101690533B (zh) | 一种红枣保健饮料的制作方法 | |
CN101940284B (zh) | 甘薯提取物及其应用 | |
KR100973087B1 (ko) | 농산부산물을 이용한 당뇨병 치유용 건강기능식품의 제조방법 및 그 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091104 |